MHC Class I and II Antigen Presentation

Introduction

In our last lesson, we focused on the role of Antigen-Presenting Cells (APCs), establishing that dendritic cells are the key messengers that capture signs of danger (like tumor antigens), travel to lymph nodes, and present these antigens to T-cells. We learned that they display these antigens on special "trays" called Major Histocompatibility Complex (MHC) molecules.

Today, we will zoom in on those trays. The learning outcome for this lesson is to explain the process of antigen presentation via MHC class I and MHC class II molecules. We will dissect the two distinct molecular pathways that cells use to process and display antigens. Understanding this distinction is crucial, as these two pathways are responsible for alerting the immune system to different types of threats and for activating different types of T-cells to deal with them. This forms the absolute foundation for understanding how T-cells recognize and attack cancer.

What are MHC Molecules?

Major Histocompatibility Complex (MHC) molecules are a set of proteins found on the surface of cells that are essential for the adaptive immune system to recognize foreign molecules. In humans, these are also known as Human Leukocyte Antigens (HLA), a term you will frequently encounter in clinical and research settings.

There are two main classes we will focus on:

• MHC Class I
• MHC Class II

To get a quick, memorable overview of these molecules and their core function, let's start with a short video.

As the video highlights, the most fundamental difference lies in which cells express these molecules and which T-cells they communicate with. This difference is a direct result of the two distinct antigen-processing pathways inside the cell.

The Two Pathways of Antigen Presentation

The immune system needs to detect two different kinds of threats:

1. Internal threats: A cell that has been corrupted from within (e.g., infected by a virus or has become cancerous).
2. External threats: Invaders that are outside the cells (e.g., bacteria in the bloodstream or cellular debris).

To handle this, two separate but parallel systems of surveillance evolved: the MHC Class I and MHC Class II pathways.

The MHC Class I Pathway: A Status Report from Inside the Cell

The MHC Class I pathway is the mechanism by which all nucleated cells in your body constantly report their internal health status to the immune system. Think of it as every cell showing a sample of the proteins it is currently making.

• What is presented? Peptides from endogenous antigens—proteins made inside the cell's cytoplasm. In a healthy cell, these are normal self-proteins, which the immune system ignores. In a cancer cell, these can be mutated proteins, or neoantigens, which the immune system can recognize as foreign.
• Who recognizes it? CD8+ Cytotoxic T-cells. If a CD8+ T-cell recognizes a "non-self" peptide on a cell's MHC Class I, its job is to kill that cell.

The video below provides a clear, animated walkthrough of this intracellular process.

To solidify this, let's review the process with a detailed written description and diagram from a core immunology resource.

The key concept here is that every nucleated cell uses its MHC-I molecules to display a snapshot of its internal protein production. This allows CD8+ T-cells to perform immune surveillance, constantly checking cells for signs of viral infection or cancerous transformation.

The MHC Class II Pathway: Presenting Dangers from the Outside World

The MHC Class II pathway is a more specialized system used only by professional Antigen-Presenting Cells (APCs)—the dendritic cells, macrophages, and B-cells we discussed in the previous lesson. Their job is to patrol for external threats, engulf them, and show the resulting peptides to the "generals" of the immune army.

• What is presented? Peptides from exogenous antigens—proteins that originated outside the cell and were taken in via phagocytosis or endocytosis. This could be a bacterium, or importantly for oncology, proteins from a dead cancer cell that the APC has cleaned up.
• Who recognizes it? CD4+ Helper T-cells. When a CD4+ T-cell recognizes a peptide on an APC's MHC Class II, its job is not to kill, but to become activated and "help" orchestrate a larger, more targeted immune response.

The process for handling external antigens is different, as it must prevent them from mixing with the internal antigens destined for MHC Class I.

Let's return to the Immunopaedia resource to understand this second pathway.

Your biochemistry background provides a good foundation for appreciating the elegance of this system. The cell uses compartmentalization (ER vs. endosomes) and molecular placeholders (the invariant chain) to ensure the right peptides are loaded onto the right MHC class.

Summary: Two Pathways for Total Surveillance

The two pathways work in concert to provide comprehensive immune surveillance. The image below provides a fantastic side-by-side comparison of the entire process, from antigen source to T-cell interaction.

Here is a summary table comparing the key features:

Relevance to Oncology and Immunotherapy

This dual-pathway system is at the heart of cancer immunology.

1. MHC Class I on Tumor Cells: A cancer cell that develops mutations will produce abnormal proteins (neoantigens). The MHC-I pathway processes these neoantigens and displays them on the cell surface. This is the primary signal that flags the cancer cell for destruction by CD8+ cytotoxic T-cells. A major goal of many immunotherapies is to boost the ability of these CD8+ T-cells to find and kill tumor cells.

2. MHC Class II on APCs: When tumor cells die, nearby dendritic cells (APCs) engulf the debris. They use the MHC-II pathway to process the tumor proteins and present them to CD4+ helper T-cells in the lymph node. These helper T-cells are critical for a robust and sustained anti-tumor response; they help activate the CD8+ killer T-cells and coordinate other arms of the immune system.

However, tumors are clever. A common way for them to evade the immune system is to disrupt the MHC-I pathway, making themselves "invisible" to CD8+ T-cells. Understanding this mechanism of resistance is a major focus of current research.

Conclusion

In this lesson, we have dissected the two fundamental pathways of antigen presentation, which are central to how the adaptive immune system sees the world.

Key Takeaways:

• MHC Class I Pathway: Presents endogenous (internal) peptides, is active in all nucleated cells, and signals to CD8+ cytotoxic T-cells. It is the cell's internal health report.
• MHC Class II Pathway: Presents exogenous (external) peptides, is restricted to professional APCs, and signals to CD4+ helper T-cells. It is the scout's report on dangers in the environment.
• The molecular machinery for each pathway (proteasome/TAP vs. invariant chain/CLIP/HLA-DM) is distinct and ensures the correct peptides are loaded onto the correct MHC class.
• In oncology, the MHC-I pathway allows for direct recognition and killing of tumor cells, while the MHC-II pathway is essential for initiating and orchestrating the overall anti-tumor response.

Preview of the Next Lesson:

We have now established how CD8+ and CD4+ T-cells are shown their respective antigens. The logical next step is to explore what they do once they are activated. In the next lesson, we will contrast the roles of CD8+ cytotoxic T-cells and CD4+ helper T-cells in an anti-tumor immune response, detailing their specific functions and how they work together to eliminate cancer.